en.Wedoany.com Reported - Tempest Therapeutics (Nasdaq: TPST) announced the appointment of Drake Richey and John Yee, M.D., M.P.H., as independent directors, effective June 4, 2026. Richey and Yee bring decades of experience in corporate finance and therapeutic product development to the board. Dr. Matt Angel, President and CEO of Tempest, stated that over the past few months, the company has built a pipeline of CAR-T cell therapy candidates aimed at providing safe and effective treatments for patients with advanced cancer. The addition of the new directors will help the company achieve its vision of offering meaningful treatment options for cancer patients who have failed prior therapies or experienced relapse, and support the company's focus on driving growth and disciplined capital allocation.
Drake Richey currently serves as President of Bush & Company, a firm providing investment strategy, risk management, and multi-generational planning advisory services to high-net-worth families and business owners. Previously, he served as President of Life Check, Vice President and Portfolio Manager at Wells Fargo, and Director at Fitch Ratings. Richey is a founding member of the Boston chapter of the Exit Planning Institute and has served on the boards of DEAF Inc., International Fellowship House, and Park Street Church. He holds a Bachelor of Science degree from Trinity College.
John Yee currently serves as Senior Vice President of Medical Affairs at Apnimed, Inc. Previously, he served as Chief Medical Officer at Sobi North America, Senior Vice President of Medical Affairs at Flexion Therapeutics, Inc., Senior Vice President and Head of Global Medical Affairs at Vertex Pharmaceuticals, Inc., Vice President of Medical Affairs, Safety, and Operations at Intarcia Therapeutics, Inc., and Vice President, U.S. Chief Medical Officer, and Head of U.S. Diabetes Medical Affairs at AstraZeneca Pharmaceuticals, and held several medical leadership roles at Genzyme Corporation. Yee earned his M.D. from Harvard Medical School and an M.P.H. in Healthcare Management from the Harvard T.H. Chan School of Public Health. He has held leadership roles at Boston Children's Hospital, served as a faculty member at Harvard Medical School, and served as an independent director of Comera Life Sciences.
Tempest Therapeutics is a clinical-stage biotechnology company dedicated to developing an advanced pipeline of CAR-T cell therapy candidates to treat cancer, headquartered in Brisbane, California.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
